Author

Yuko Tanaka

Institutions: Asahi General Hospital, Dokkyo Medical University Hospital

Observed institutions: Boehringer Ingelheim (Japan), Asahi General Hospital, Dokkyo Medical University Hospital, Dokkyo Medical University

ORCID: 0000-0002-8563-2554

Observed ORCID: 0000-0002-8563-2554

OpenAlex ID: A5065886815

Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report

2024 · Yuko Tanaka, Naoya Ikeda, et al. · International Cancer Conference Journal · 3

A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.

2024 · Toshihiko Doi, Noboru Yamamoto, et al. · Journal of Clinical Oncology · 1

Multiple endocrine neoplasia type 1 with MEN1 variant of unknown significance, in a patient after the diagnosed of pancreatic neuroendocrine neoplasia

2024 · Yuko Tanaka, Takafumi Niitani, et al. · International Cancer Conference Journal · 1

A case of advanced breast cancer with Gitelman syndrome

2023 · Yuko Tanaka, Miyuki Muramatsu, et al. · International Cancer Conference Journal · 1

Immunotherapy-Based Combination Therapy for the Successful Treatment of Coexisting Primary and Axillary Accessory Breast Cancers: A Case Report

2025 · Yuko Tanaka, Yoshio Suzuki · Cureus

Works count: 5

Citation count: 6

H-index: 1

I10-index: